12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

AMR101 regulatory update

FDA accepted for review an NDA submitted by Amarin for AMR101 to treat hypertriglyceridemia in patients with triglyceride levels >=500 mg/dL. The...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >